The 42nd Annual Meeting of the European Society for Blood and Marrow Transplatation will bring together leaders in the field to discuss cellular immunotherapies including CARTs, the most recent clinical results from haploidentical transplants and the newest biological advances in stem cell transplantation. The program includes:

  • 32nd Meeting of the Nurses Group
  • 15th Meeting of the Data Management Group
  • 8th Meeting of the Quality Management Group
  • 5th Cell Therapy Day
  • 5th Paediatric Day
  • 10th Patient, Family and Donor Day (2 April, 2016)

EBMT 2016

03–06 April 2016 | Feria Valencia, Valencia, Spain

EBMT 2016

03–06 April 2016 | Feria Valencia, Valencia, Spain

The 42nd Annual Meeting of the European Society for Blood and Marrow Transplatation will bring together leaders in the field to discuss cellular immunotherapies including CARTs, the most recent clinical results from haploidentical transplants and the newest biological advances in stem cell transplantation. The program includes:

  • 32nd Meeting of the Nurses Group
  • 15th Meeting of the Data Management Group
  • 8th Meeting of the Quality Management Group
  • 5th Cell Therapy Day
  • 5th Paediatric Day
  • 10th Patient, Family and Donor Day (2 April, 2016)
Defibrotide: Redefining the treatment for severe veno-occlusive disease (sVOD) 3:06
Defibrotide: Redefining the treatment for severe veno-occlusive disease (sVOD)
Paul Richardson • 4 Apr 2016
Mohamad Mohty on EBMT 2016 3:01
Mohamad Mohty on EBMT 2016
Mohamad Mohty • 4 Apr 2016
Blinatumomab for treating ALL 1:09
Blinatumomab for treating ALL
Giovanni Martinelli • 3 Apr 2016
Monoclonal antibodies for difficult-to-treat multiple myeloma 2:14
Monoclonal antibodies for difficult-to-treat multiple myeloma
Mohamad Mohty • 4 Apr 2016
Transforming healthcare with Twitter: A physician’s perspective 4:12
Transforming healthcare with Twitter: A physician’s perspective
Navneet Majhail • 4 Apr 2016
Graft-versus-host disease (GvHD): Advances at EBMT 2016 3:12
Graft-versus-host disease (GvHD): Advances at EBMT 2016
Mohamad Mohty • 4 Apr 2016
New monoclonal antibodies for ALL treatment 1:58
New monoclonal antibodies for ALL treatment
Arnon Nagler • 4 Apr 2016
Engaging healthcare professionals and patients with social media 3:28
Engaging healthcare professionals and patients with social media
Michael Thompson • 4 Apr 2016
Change of landscape in CLL treatment 1:53
Change of landscape in CLL treatment
John Gribben • 4 Apr 2016
Strategies to reduce graft-versus-host disease (GvHD) 1:48
Strategies to reduce graft-versus-host disease (GvHD)
Miguel-Angel Perales • 4 Apr 2016
Key questions in the field of CD19 CAR T-cell therapy 4:24
Key questions in the field of CD19 CAR T-cell therapy
Catherine Bollard • 4 Apr 2016
Separation of graft-versus-leukemia from graft-versus-host disease (GvHD) 1:46
Separation of graft-versus-leukemia from graft-versus-host disease (GvHD)
Arnon Nagler • 4 Apr 2016
Predicting and diagnosing TB and CMV in hematopoietic cell transplant recipients 1:04
Predicting and diagnosing TB and CMV in hematopoietic cell transplant recipients
Roy Chemaly • 4 Apr 2016
Improving the assessment of response in relapsed MM 1:47
Improving the assessment of response in relapsed MM
Bruno Paiva • 4 Apr 2016
Big topics for nurses at EBMT 2016 1:08
Big topics for nurses at EBMT 2016
Arno Mank • 4 Apr 2016
The not-invented-here syndrome in nursing research 1:38
The not-invented-here syndrome in nursing research
Arno Mank • 4 Apr 2016
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals